2015;42(2):92-95. 322. Hallevi H, Albright KC, Martin-Schild S, et al. Anticoagulation after cardioembolic stroke: to bridge or not to bridge? Arch Neurol. 2008;65(9):1169-1173. 323. Kim TH, Kim JY, Mun HS, et al. Heparin bridging in warfarin anticoagulation therapy initiation could increase bleeding in non- valvular atrial brillation patients: a multicenter propensity- matched analysis. J Thromb Haemost. 2015;13(2):182-190. 324. Audebert HJ, Schenk B, Tietz V, Schenkel J, Heuschmann PU. Initiation of oral anticoagulation after acute ischaemic stroke or transient ischaemic attack: timing and complications of overlapping heparin or conventional treatment. Cerebrovasc Dis. 2008;26(2): 171-177. 325. Seiffge DJ, Traenka C, Polymeris A, et al. Early start of DOAC after ischemic stroke: Risk of intracranial hemorrhage and recurrent events. Neurology. 2016;87(18):1856-1862. 326. Toyoda K, Arihiro S, Todo K, et al. Trends in oral anticoagulant choice for acute stroke patients with nonvalvular atrial brillation in Japan: the SAMURAI-NVAF study. Int J Stroke. 2015;10(6):836- 842. 327. Arihiro S, Todo K, Koga M, et al. Three-month risk-bene t pro le of anticoagulation after stroke with atrial brillation: the SAMURAI-Nonvalvular Atrial Fibrillation (NVAF) study. Int J Stroke. 2016;11(5):565-574. 328. Terent A, sberg S, Oldgren J, Hijazi Z, Norrving B. Antikoagulantia efter akut ischemisk stroke med f rmaks immer Fr gan om r tt tidpunkt f r ins ttning kr ver randomiserad klinisk pr vning [in Swedish]. Lakartidningen. 2016;113. 329. Hong KS, Choi YJ, Kwon SU; Triple AXEL Investigators. Rationale and design of Triple AXEL: trial for early anticoagulation in acute ischemic stroke patients with nonvalvular atrial brillation. Int J Stroke. 2015;10(1):128-133. 330. Lovelock CE, Molyneux AJ, Rothwell PM, Oxford Vascular S. Change in incidence and aetiology of intracerebral haemorrhage in Oxfordshire, UK, between 1981 and 2006: a population-based study. Lancet Neurol. 2007;6(6):487-493. 331. 